SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Biotech gets USFDA’s approval for Bortezomib for injection

03 Jun 2025 Evaluate

Medicamen Biotech has received its first Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Bortezomib for injection 3.5 mg. The ANDA is for Bortezomib for Injection, 3.5 mg Single-Dose Vial. The FDA has determined that Bortezomib for Injection, 3.5 mg Single-Dose Vial, is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Velcade for Injection, 3.5 mg/vial, of Takeda Pharmaceuticals U.S.A. Inc. (NDA-021602).

This achievement marks a major step forward in its commitment to enter in regulated markets. The Bortezomib API has been developed in its own R&D and API has been manufactured at Shivalik Rasayan having USDMF 036171, It is a testament to its capabilities to successfully develop and commercialize products using in house R&D capabilities and own API facility, built over last few years.it also demonstrate the company’s dedication to stringent quality standards, robust regulatory compliance, and adherence to Current Good Manufacturing Practices (cGMP).

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.


Medicamen Biotech Share Price

243.75 1.30 (0.54%)
13-Apr-2026 14:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.90
Dr. Reddys Lab 1231.20
Cipla 1212.00
Zydus Lifesciences 923.80
Lupin 2322.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×